Mathieu et al. (2005) reported that selective CCKBR antagonists delayed the growth of C32 human melanoma xenografts, which may be attributed to their inhibitory effect on neoangiogenesis. Because C32 melanoma cells neither expressed CCKBR nor CCKAR, it is unlikely that CCKBR antagonists exerted their antitumor effects on C32 melanoma xenografts through direct effects on melanoma cells (Mathieu et al., 2005). Here, CCKAR is linked to melanoma.